Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objectives: To examine the efficacy of intralesional collagenase Clostridium histolyticum ( CCH ) in defined subgroups of patients with Peyronie's disease ( PD ). Patients and Methods: The efficacy of CCH compared with placebo, assessed from baseline to week 52, was examined in subgroups of participants from the Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies ( IMPRESS ) I and II . The subgroups were defined according to: severity of penile curvature deformity at baseline (30–60° [ n = 492] and 61–90° [ n = 120]); PD duration (1 to ≤2 [ n = 201], >2 to ≤4 [ n = 212] and >4 years [ n = 199]); degree of plaque calcification (no calcification [ n = 447], non‐contiguous stippling [ n = 103] and contiguous calcification that did not interfere with injection of CCH [ n = 62]); and baseline erectile function (International Index of Erectile Function [ IIEF ] scores 1–5 [ n = 22], 6–16 [ n = 106] and ≥17 [ n = 480]). Results: Reductions in penile curvature deformity and PD symptom bother were observed in all subgroups. Penile curvature deformity reductions were significantly greater with CCH than with placebo for the following subgroups: baseline penile curvature 30–60° and 61–90°; disease duration >2 to ≤4 years and >4 years; no calcification; and IIEF score ≥17 (high IIEF ‐erectile function score; P < 0.05 for all). PD symptom bother reductions were significantly greater in the CCH group for: penile curvature 30–60°; disease duration >4 years; no calcification; and IIEF score 1–5 (no sexual activity) and ≥17 ( P < 0.05 for all). Conclusions: In this analysis, clinical efficacy of CCH treatment for reducing penile curvature deformity and PD symptom bother was found across subgroups. In the IMPRESS I and II overall, adverse events ( AE s) were typically mild or moderate, although treatment‐related serious AE s, including corporal rupture or penile haematoma, occurred. Future studies could be considered to directly assess the efficacy and safety of CCH treatment in defined subgroups of PD patients, with the goal of identifying predictors of optimum treatment success.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelbard, M., Goldstein, I., Hellstrom, W. J. G., McMahon, C. G., Smith, T., Tursi, J., Jones, N., Kaufman, G. J., & Carson, C. C. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.01.087 · Cited by 466
Self-citationThe Chronology of Depression and Distress in Men with Peyronie's Disease
Nelson, C. J., Diblasio, C., Kendirci, M., Hellstrom, W., Guhring, P., & Mulhall, J. P. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00895.x · Cited by 255
Hellstrom, W. J. G., Feldman, R., Rosen, R. C., Smith, T., Kaufman, G., & Tursi, J. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.01.090 · Cited by 210
Self-citationRisk Factors for Emotional and Relationship Problems in Peyronie's Disease
Smith, J. F., Walsh, T. J., Conti, S. L., Turek, P., & Lue, T. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00949.x · Cited by 206
Peyronie’s Disease Intervention Trials: Methodological Challenges and Issues
Müller, A., & Mulhall, J. P. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01081.x · Cited by 80
Paulis, G., & Brancato, T. (2012) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152812798889321 · Cited by 60
Cited by
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
Peyronie’s disease: Contemporary evaluation and management
Ziegelmann, M. J., Bajic, P., & Levine, L. A. (2020) · International Journal of Urology · doi:10.1111/iju.14230 · Cited by 86
Bella, A. J., Lee, J. C., Grober, E. D., Carrier, S., Benard, F., & Brock, G. B. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.5255 · Cited by 68
Nonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Ziegelmann, M. J., Trost, L. W., Russo, G. I., & Levine, L. A. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.11.271 · Cited by 31
Metadata
- Authors
- Lipshultz, L. I., Goldstein, I., Seftel, A. D., Kaufman, G. J., Smith, T. M., Tursi, J. P., & Burnett, A. L.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2015-05-18
- Volume
- 116
- Issue
- 4
- Pages
- 650-656
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2039205641
- Cited by
- 120
- References
- 6
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies. https://app.cochat.ai/papers/10.1111/bju.13096
- The paper
- Lipshultz, L. I., Goldstein, I., Seftel, A. D., Kaufman, G. J., Smith, T. M., Tursi, J. P., & Burnett, A. L. (2015). Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studies. BJU International. https://doi.org/10.1111/bju.13096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.